Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So make a decision
Long gone, just stopped by for my friends
Best of life for everyone
Fabulous Igm, you know why state of Louisiana stepped in
Sf screwed it up
Ruth is the big winner here & there is no winner b/c
Oxford has non cold storage 10 years out
:}
Do you know why I'm here ?
I'm out, big difference in 01 & 001 & 0001
Who changed the filling ?
I'm done here but I could care less about you......!!!!!!!!!!!!
Much less Fort Dietrich
Good luck, you are going to need it w/ a 2000 to one
What makes you think it's going private ? Don't ok....!!!! Tell your wife I said hi.... The difference in Chit Creek & you is nothing more that Dr S......!!!!!!
Nothing new on Anergis today
LOL no LOL
Nothing new on Anergis today
LOL
Thanks brother
It's an age related thing & pure economics from a market standpoint
I might keep what I have left & I'll be in the background but not reading here. I'll get a heads up if something breaks & I'll be all over it.
Yw AhsokaXC
Great group of folks here & it's been a wonderful experience, wouldn't trade it for anything
Later folks
WJFS CEO Robert Donohue bod Anergis
meaning Amy Wyss might as well be
https://www.fiercepharma.com/vaccines/new-financing-helps-anergis-take-allergy-vaccine-to-phase-iii
I'll be out soon meaning it should rise before long b/c RK & the insiders are just spiteful people & I'm ok with it, not my first rodeo
My work is done here, glta & I think you will have a good year
Later folks
It's the closest path to rev's unless
Hiv gets fast tracked
Without improvement, I won't be holding this thing another year. It's easier to make money elsewhere.
Glta
My bad
Has to be this month or next, those assets are worth something. I'll keep looking but the bk court website isn't giving it up yet, thanks.
Initiation: 12/05/2022
https://www.northdata.com/?id=5715455426691072
I missed it also
but yah anything here @ all
later
See the difference in Nashville
Just a thing
Watching GB S in L V
Get it ?
Watching Nashville
LOL
Third line from left to right
Clearance in the
sketchy form
Clearance in the
ordinary form
Suspension of the
bankruptcy due to lack of assets
Below those
Deuxième assemblée
des créanciers is Second assembly creditors
Which I think is done & what Ronnie was trying to tell us in June
Réalisation is Achievement
&
Distribution des deniers is Distribution of Funds
Below that @ the end, Clôture is obviously closure
&
rapport final is report final
Da data gotta be in for Hiv if we use Breslin Ag as a template & Anergis news in what December around the time of the Mymx bod meeting b/c
25 Jan 2021 as Anergis SA
According to the decision of its general meeting of 29 October 2020, the company has pronounced its dissolution
Happy up coming holidays folks, later
Compared to Mymx or even Anergis
https://www.cbinsights.com/company/redwood-bioscience/financials
Unless Anergis lands someplace worth while or the Hiv data comes in good enough
We need a real CEO & BOD but I'm only stating the obvious
https://www.fiercebiotech.com/cro/catalent-increases-stake-redwood-bioscience-0
12 employees, see any investment by Catalent in Mymx ?
I mean if Vir can do what they did
https://www.linkedin.com/posts/mike-blank-9626442_triphase-accelerator-announces-positive-updated-activity-6901936283468353536-sezd
I am excited to share results from a Phase 1 study of a drug that was discovered and developed by Redwood Bioscience -- the Company I founded in 2008. It took 14 years to reach this point -- Redwood is now part of Catalent Pharma, acquired in 2014, and this drug was subsequently licensed to TriPhase Accelerator as noted, but it was all invented by my core Redwood Bioscience team, in a start-up lab. We had old equipment, almost no money, and even less experience, but somehow we made it all work :)
Uh, the ole dreaded Redwood Bioscience
Small World, eh
:}
Why didn't they use Click Chemistry in the Mymetics / Catalent patent ?
B/c it's outdated so that is what another 5 years @ the Nih gets you but huge data coming
Nice lake they have over there
LOL
Applications of Click Chemistry in the Development of HIV Protease Inhibitors
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077553/
Inhibitors of HIV-1 Protease via In Situ Click Chemistry
https://grantome.com/grant/NIH/F32-GM077733-02
Technology license
The Scripps Research Institute has a portfolio of click-chemistry patents.[55] Licensees include Invitrogen,[56] Allozyne,[57] Aileron,[58] Integrated Diagnostics,[59] and the biotech company baseclick,[60] a BASF spin-off created to sell products made using click chemistry.[61] Moreover, baseclick holds a worldwide exclusive license for the research and diagnostic market for the nucleic acid field. Fluorescent azides and alkynes also produced by such companies as Active Motif Chromeon[62] and Cyandye.[63]
https://en.wikipedia.org/wiki/Click_chemistry
Click Chemistry Conjugations
Utility of this chemistry for site-specific ADCs has been demonstrated [21] and one (Trph-222 from Triphase - licensed from Catalent) has recently entered clinical trial [22].
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444748/
Bertozzi’s work has spun out many biotech startups, including Lycia Therapeutics, which focuses on degrading previously “undruggable” extracellular protein targets, and Redwood Bioscience, which was later acquired by Catalent.
https://www.statnews.com/2022/10/05/nobel-prize-chemistry-2022/
The technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two ‘click’, a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds.
Click chemistry can be applied to multiple drug classes, including small molecules, antibodies, and immune cell engagers. Click chemistry could enable the precise localization and activation of any of these therapies to the tumor site, thereby improving efficacy,
https://www.statnews.com/sponsor/2021/12/22/it-takes-two-the-future-of-click-chemistry-therapeutics/
IO Biotech Headquarters: Denmark
https://www.sec.gov/Archives/edgar/data/927761/000095015208001236/l30222aexv10w1.htm
STATENS SERUM INSTITUT, whose administrative office is at 5 Artillerivej, DK-2300 Copenhagen, Denmark, represented by Dr Frank Espersen,Executive Vice- President or Dr. Nils Strandberg Pedersen, President & Chief Executive Officer of Statens Serum Institut;
Methods of improving efficacy of allergy vaccines
They may be added as lipo-peptides or attached to a lipophilic anchor already present in the virosome structure. According to one preferred aspect of the invention it is contemplated that the peptides be incorporated into the virus-like particle or virosome using click chemistry which allows for specific binding of the peptide to a selected counterpart structure.
https://patents.google.com/patent/WO2020121062A1/en
VAXCYTE S 1
Better Chemistry
We also employ a rapid and less harsh chemistry method called copper-free click chemistry to site-specifically conjugate the polysaccharides to eCRM. We believe this distinctive technique is a better controlled, more efficient and faster method of conjugation relative to conventional chemistry used to make traditional PCVs. The click chemistry conjugation reaction is designed to cause less damage to the critical immunogenic epitopes on the protein carrier or the target antigen.
The click chemistry we use for site-specific conjugation may also minimize damage to the critical immunogenic epitopes on the protein carrier and the polysaccharides through milder and shorter reactions, while other PCVs use conventional chemistries that involve harsher and longer reaction conditions.
The pAMF amino acids have a specific structure that enables eCRM to participate in the site-specific click chemistry conjugation reaction with activated pneumococcal polysaccharides.
Click chemistry provides for a conjugation reaction that is quick, consistent and high-yielding, and which we optimized to be standardized across the various polysaccharides. Through statistical design of experiment, or DoE, studies, we have gained a significant understanding of which variables to adjust to maximize product quality and, accordingly, immunogenicity in rabbit models.
https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328ds1.htm
In addition, the S protein was covalently coupled via its His-tag to
a click chemistry lipid present in the virosomal membrane.
2.4. Virosomes Preparation
To the supernatant, the lipid 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC) (Merck) and the click chemistry lipid dicyclobenzooctyl phosphatidylethanolamine (DBCO-PE) (Avanti Polar Lipids, Alabaster, AL, USA) were dissolved in OEG, and added OEG was then removed by batch chromatography on polystyrene beads (BioBeads SM2) as described; resulting homogenous virosomes were sterilized by 0.22 µm filtration.
2-azidoethyl thiophosphodichlorate (ATPD) was synthesized and purified as described
(Jia, S. et al., 2020) by Acme Bioscience (Palo Alto, CA, USA). S protein was dialyzed against 50 mM HEPES pH 8.5 for 4 h and then mixed with ATPD at a 200:1 ratio of ATPD to protein for 1 h at RT. The product was dialyzed overnight against 2000 volumes of buffer (145 mM NaCl, 5 mM HEPES, 1 mM EDTA, pH 7.4). The resulting S-azide conjugate product was incubated with virosomes for at least 24 h at 25 ?C resulting in covalent coupling of S to virosomes through azide-DBCO-PE click chemistry.
3.3. Conjugation of SARS-CoV-2 Spike Protein to Virosomes
Purified S protein was covalently coupled to virosomes through DBCO-azide click
chemistry, and the presence of S protein on the virosomes through the exposure of key
epitopes on the protein and the binding of an ACE2-Fc were confirmed by ELISA (Figure 4). Results indicate that the S protein as displayed on the surface of the virosomes is capable of binding to the ACE2 receptor and is also recognized by CR3022 and by all the tested neutralizing antibodies toward various epitope clusters. This binding capacity is also preserved on virosomes-S stored at 4 ?C for 1 month, as similar IC50 values were obtained for t = 0 and t = 1 month, thus demonstrating an enhanced stability of virosomes-S.
These results suggest that S protein covalently coupled via its
His tag to a click chemistry lipid present in the virosomal membrane results in an oriented display of the protein and properly exposes its receptor binding domain (RBD) involved in ACE2 binding on target cells, thus, theoretically favoring the induction of relevant neutralizing antibodies toward RBD for blocking cell infection
Insect Cells for High-Yield Production of SARS-CoV-2 Spike Protein: Building a Virosome-Based COVID-19 Vaccine Candidate
https://pubmed.ncbi.nlm.nih.gov/35456687/
A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike
4 times
https://www.nature.com/articles/s41598-022-07590-w
From the Phospene post
Study investigates the production of a virosome-based COVID-19 vaccine candidate
The study
In a recent study published in Pharmaceutics, different signal peptides, baculovirus transfer vectors, cell lines, infection techniques, and formulation buffers were investigated with the purpose of building a scalable bioprocess to generate high-quality S protein for incorporation in a virosome-based COVID-19 vaccine candidate.
The stability, oligomeric state, and binding capability of the generated protein to the angiotensin-converting enzyme 2 (ACE2) receptor and selected neutralizing SARS-CoV-2 antibodies were all evaluated in depth. The S protein was also covalently linked to a click chemistry lipid in the virosomal membrane through its polyhistidine- (His)-tag.
https://www.news-medical.net/news/20220418/Study-investigates-the-production-of-a-virosome-based-COVID-19-vaccine-candidate.aspx
Recent trends in click chemistry as a promising technology for virus-related research
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173221/
About the time Baylor showed up. Speaking of Baylor, it's almost November 2 years ago & Ronnie didn't pr what he should have & pr ed what he shouldn't have ?
PCI Biotech is in Norway right
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) Kvistgaard, Denmark
https://www.pcibiotech.no/news/pci-biotech-initiates-research-collaboration-with-bavarian-nordic
Tucker Carlson vaccine powerful editors
Several of them very powerful people in scientific review journals
within the last week
but that episode doesn't show up w/ a search
Funny how that happens but I'm not done looking for it b/c it's not like we didn't already know that
Ronnie & gang isn't fooling anyone or scaring anyone
It's October right,
BOO
Hang in there Steel
That is way too generous
for Mr. Kempers that is
ROTFLMAO
Continued prayers for Steel & the Mymx folks including Ronnie LOL
Utah gotta be looking pretty gewd right now
Shouldn't we ?
Proof isn’t *always* in the pudding.
Some truths exist way beyond the realm of facts, data and details.
Take a step back and revel in the big picture?
That is asking for a lot after all b/c it's almost Oct & we all know what data is due in Oct but he'll try to hide it, always does. Gotta make sure the consultants get their due in Nov so that the Bod can decide in Dec.
Later
When is it ?
A death cross, he worked so hard for it
Just imagine how proud he must be paying a consulting firm for the last pr
SMH
Denise is a molecular immunologist. Her research focuses on developing novel immunotherapeutics and immunodiagnostics for complex pathogens that cause chronic diseases, using malaria as a model. Much of her career has focused on malaria immunology and vaccine development.
She was awarded a National Academy of Sciences Postdoctoral Fellowship to work at the United States Naval Medical Research Center with Stephen Hoffman on malaria vaccine development. After appointments as Director of Basic and Preclinical Research & Development and then Scientific Director of the US Navy Malaria Program, she returned to Australia in 2007.
She has strong expertise in the process of vaccine development, spanning the complete vaccine development pipeline from discovery to clinical testing, including regulatory aspects and IND applications.
https://research.jcu.edu.au/portfolio/denise.doolan/
Hail Oxford
D. NEGOTIATION & DUE DILIGENCE (6 - 8 weeks)
In May 2022, the Company entered into engagement agreements with two biotech consulting firms to source potential licensing, financing and/or acquisition opportunities for the Company under customary compensation terms.
https://www.otcmarkets.com/filing/html?id=15814217&guid=JF--kWqp5N5HJth
What is it, 20 weeks now
E. FINALIZATION & CLOSING (approx. 4 weeks)
A clinical study of MYM-V101
Status: Planning
Phase of Trial: Phase I
Latest Information Update: 06 May 2019
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153386495
28 May 2022 No recent reports of development identified for phase-I development in HIV-1-infections(Prevention) in Belgium (IM, Injection)
https://adisinsight.springer.com/drugs/800021858
Where did MYM-201 go ?
https://adisinsight.springer.com/search
Year 4 or now 5 @ the NIH via all over the world, Texas & Louisiana being the main players or more like hiders in partner
LOL
Mucosal vaccination: Strategies to induce and evaluate mucosal immunity
https://www.frontiersin.org/articles/10.3389/fimmu.2022.905150/full
LSU & Andreas Frey
https://books.google.com/books?id=GkZxEAAAQBAJ&pg=PA235&lpg=PA235&dq=MYM+V201&source=bl&ots=K-DDW_O7Fa&sig=ACfU3U1F7jhj0MWCY4zxD4J2N5I1tHtaQA&hl=en&sa=X&ved=2ahUKEwixj8Sa4qP6AhXQpIkEHVovAx4Q6AF6BAgeEAM#v=onepage&q=MYM%20V201&f=false
Dr. Kozlowski is a mucosal immunologist who received her PhD from the University of Alabama at Birmingham and performed her post-doctoral training at Harvard Medical School. She is currently an Associate Professor at the LSU Medical School in New Orleans. She has expertise in mucosal vaccines, secretion collection methods, and IgA. Over the last 20 years, she has consulted or actively participated in numerous clinical and preclinical studies testing a variety of mucosal and parenteral vaccines. However, the majority of her research is focused on functions of antiviral antibodies and development of vaccines to HIV-1 and SARS CoV-2.
https://loop.frontiersin.org/people/42436/bio
Nicholas J Mantis
Editorial Roles
Guest Associate Editor for
Vaccines and Molecular Therapeutics
Frontiers in Immunology
Open for submissions
Review Editor for
Mucosal Immunity
Frontiers in Immunology
https://loop.frontiersin.org/people/25921/overview
Washington State University & Lausanne, Switzerland is following you LOL
From above now 2,147 total views & some tweets, way too many in the float on that one but that is jmho
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
https://www.frontiersin.org/articles/10.3389/fimmu.2022.788619/full
Edited by Andreas Frey
MYM-V201 data just about ready, right Ronnie LOL
Big ole round of applause for Ghent Belgium
A perfect fit
This information is subject to the disclosure requirements in MAR (regulation (EU) No. 596/2014 on market abuse) as implemented in Norway in accordance with section 3-1 of the Securities Trading Act.
LOL
No worries, Spokane has that
Under control
LOL
It will work for me
:}
Later
WHO announces new biomanufacturing training hub in South Korea
https://www.devex.com/news/who-announces-new-biomanufacturing-training-hub-in-south-korea-102740
Moderna sets sights on $200M vaccine factory in Seoul: report
https://www.fiercepharma.com/manufacturing/moderna-sets-sights-200m-vaccine-factory-seoul-report
SK bioscience to manufacture Novavax's Omicron COVID-19
https://www.biopharma-reporter.com/Article/2022/07/19/sk-bioscience-to-manufacture-novavax-s-omicron-covid-19-vaccine
South Korea’s Ambition to Become a Global Vaccine Hub
https://thediplomat.com/2021/08/south-koreas-ambition-to-become-a-global-vaccine-hub/
Korea is already home to leading biosimilars producers such as SK Bioscience, GC Pharma, and Samsung Biologics. Korean companies have also figured prominently in the global COVID response, providing contract manufacturing services to diverse vaccine developers.
https://www.weforum.org/agenda/2021/11/south-korea-vaccine-industry-global-trade-policy-tarriffs/
Ph, you may be right in that it was the Mymx biotech consulting firms but it looks so far out that it doesn't matter on that one unless South Korea can manufacture something else for Mymx. Just another total disappointment designed to take the price down right in front of Hiv data. Why would anyone buy common stock w/ that kinda debt the way this company is run.
Sanofi-Aventis To Increase S. Korea Investment By 20 Percent A Year
https://pink.pharmaintelligence.informa.com/SC066640/SanofiAventis-To-Increase-S-Korea-Investment-By-20-Percent-A-Year
Sanofi-Aventis to invest 70 bln won in Korea
Sanofi's Korean affiliate is the fifth largest recipient of clinical trial investments
In Korea, Sanofi has four legal entities in the fields of pharmaceuticals and consumer healthcare (sanofi-aventis Korea), vaccines (Sanofi Pasteur), rare disease (Genzyme Korea), and animal health (Merial Korea).
https://pharmaboardroom.com/directory/sanofi-korea/
SANOFI PASTEUR ALLIES WITH SK CHEMICALS CO. OF SOUTH KOREA ON PNEUMOCOCCAL CONJUGATE VACCINE
https://www.fiercebiotech.com/biotech/sanofi-pasteur-allies-sk-chemicals-co-of-south-korea-on-pneumococcal-conjugate-vaccine
Sanofi, Hanmi seal diabetes licence deal for up to $4.2 billion
https://www.reuters.com/article/us-sanofi-hanmi-diabetes/sanofi-hanmi-seal-diabetes-licence-deal-for-up-to-4-2-billion-idUSKCN0SU0R120151105
Sanofi's Korean union threatens a strike over pay as Big Pharmas stare down global demands
https://endpts.com/sanofis-korean-union-threatens-a-strike-over-pay-as-big-pharmas-stare-down-global-demands/
Sanofi executive others arrested as South Korean prosecutors probe vaccine cartel[
https://mlexmarketinsight.com/news-hub/editors-picks/area-of-expertise/antitrust/sanofi-executive-others-arrested-as-south-korean-prosecutors-probe-vaccine-cartel
Our manufacturing facility in Korea is our sole source of our supplies of our Quinvaxem vaccine
https://www.sec.gov/Archives/edgar/data/1126136/000110465907047370/a07-7572_120f.htm
Non-Patent Citations (3)
KIM HONG SUNG ET AL: "Effect of lipid compositions on gene transfer into 293 cells using Sendai F/HN-virosomes.", JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY. KOREA (SOUTH) 30 SEP 2002, vol. 35, no. 5, 30 September 2002 (2002-09-30), pages 459 - 464, XP009016437, ISSN: 1225-8687 *
Status Withdrawn
https://patents.google.com/patent/EP1447080A1/un
The cDNA was used for the amplification of the viral fusion gene using the following specific primers chemically synthesized from Macrogen, Korea [26].
Amplicons were visualized in ethidium bromide-stained 1% agarose gel, and size was estimated using a 1?kb DNA ruler (New England Biolabs®, USA) [27]. PCR amplicons were purified using the QIAquick PCR purification kit (Qiagen™, USA), as per the guidelines of the manufacturer. Purified products were dispatched for di-deoxy Sanger’s sequencing from Macrogen, Korea. Sequences obtained from Macrogen, Korea, were analyzed using different bioinformatics tools and online programs [28, 29]. Genetic and evolutionary relatedness of the fusion gene were analyzed, and a phylogenetic tree was constructed by the neighbor-joining method [29].
he incorporation of the plasmid in the virosome was confirmed by nested polymerase chain reaction using the following primers synthesized from Macrogen, Korea [27].
https://www.hindawi.com/journals/bmri/2021/8879277/
Sanofi union members set strike date in Korea as wage negotiations stall: report
https://www.fiercepharma.com/pharma/sanofi-union-members-set-strike-date-korea-wage-negotiation-hits-setback
Still boring, old & wore out
Untitlted
https://pesquisa.bvsalud.org/portal/?lang=esSiqueira&q=au:%22Ruprecht,%20Ruth%20M%22
Hartwell, Brittany
From that
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges.
https://pesquisa.bvsalud.org/portal/resource/esSiqueira/mdl-35273592
Dinesh Hariraju
https://www.linkedin.com/in/dineshhariraju
Fundraiser for Dinesh Hariraju by Sandeep Gupta - GoFundMe
https://www.gofundme.com/f/help-dinesh-hariraju
This is an effort to raise funds for our friend and colleague, Dinesh Hariraju, to help him heal and recover from the horrific and life-altering tragedy that befell him on the dreadful night of February 17, 2019. Dinesh was an innocent victim of a daring shooting at his own apartment in the middle of Medical center area of San Antonio, TX, by criminal and desperate gunmen, who opened fire, spraying 11 bullets in matter of seconds, nearly killing him and his expecting wife, Sujitha.
plus a follow up & the Fundraising team: Friends of Dinesh at TxBiomed